Pyrazinamide Pregnancy Warnings
Animal studies have not been reported. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Use is not recommended unless clearly needed.
US FDA pregnancy category: C
See references
Pyrazinamide Breastfeeding Warnings
Caution is recommended; benefit to mother should outweigh risk to the infant.
-Some experts recommend: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Yes
Comments:
-The WHO classifies this drug as compatible with breastfeeding; the breastfed infant should be monitored for jaundice.
-The US Centers for Disease Control and Prevention and other professional organizations state breastfeeding should not be discouraged in women taking this drug.
-Some experts recommend: Exclusively breastfed infants should be monitored for the signs/symptoms of toxicity (e.g., arthralgia, fever, hepatitis, jaundice, loss of appetite, nausea, rash, thrombocytopenia, vomiting).
See references
